Opsens Signs Landmark Supplier Agreement – Expands Optical Sensing Technology Impact Within Cardiology Segment

QUEBEC CITY, April 30, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. (“Abiomed”) for the Impella CP® heart pump.

Abiomed has awarded Opsens a five-year agreement to supply a critical component for its heart pump technology. The contract includes mutual renewal clauses. This new agreement between Opsens and Abiomed follows a co-development and license agreement to integrate Opsens’ miniature optical pressure sensor into Impella CP® heart pumps, signed in 2014.

“We are pleased to significantly expand our collaboration with Abiomed and the integration of our optical technology into the widely used Impella CP® in the United States. This partnership clearly highlights the benefits of our optical technology for cardiac applications and demonstrates the accuracy of our measurement technology as well as the quality of our manufacturing capabilities,” said Louis Laflamme, President and CEO of Opsens.

“The continued development of our original equipment manufacturer (OEM) business segment is strategically important for Opsens,” adds Laflamme. It increases the critical mass in manufacturing, further advancing the company’s improvement initiatives. This agreement allows Opsens to capitalize on the work done with Abiomed in recent years and highlights the quality of its offer to the interventional cardiology market globally.

About Opsens Inc.

Opsens focuses mainly on physiological measurements such as FFR and dPR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 60,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333

Robin Villeneuve, CPA, CA, Chief Financial Officer, 418.781.0333

Related Article: Opsens Q2 2019 Revenues Reach a Record Level